Science and the Stimulus Effect | GenomeWeb

Science and the Stimulus Effect

Premium

As the Dow plummeted toward 8,000 in 2008 and banks couldn't get bailed out fast enough, probably the last thing on everyone's mind was the state of biomedical — particularly genomic — research in the United States. Yet when the American Recovery and Reinvestment Act was signed into law in 2009 to prevent the US economy from bottoming out, investment in basic research figured prominently. Of the $787 billion that ARRA allocated, $18.3 billion was set aside for basic research, and the White House estimates that more than $1 billion of those research dollars are being spent on genomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.